Inclusion Criteria:

Patients must have histologically or cytologically confirmed adenocarcinoma of the
prostate For patients who have recurrent disease following surgery as first line therapy
("surgical failures"), the PSA requirement is 0.2 ng/ml or above; for patients who have
recurrent disease following radiation as first line therapy, the eligibility follows the
"Phoenix criteria", that is, a rise of 2 ng/mL over the PSA nadir Eastern Cooperative
Oncology Group (ECOG) performance status =< 2 Granulocytes >= 1000/uL Serum creatinine =<
2.0 mg/dl Total serum calcium > 9.0 and < 10.5 mg/dl Total bilirubin =< 2.0 mg/dl Platelet
count >=100,000/uL Hemoglobin (Hgb) >= 9 g/dL Total testosterone >= 50 ng/dL Ability to
understand and the willingness to sign a written informed consent document (either
directly or via a legally authorized representative)

Exclusion Criteria:

Serious medical illness which would limit survival to less than 3 months Active,
uncontrolled bacterial, viral or fungal infection Hemorrhagic disorder Any radiographic
evidence of metastatic disease including positive bone scan or computed tomography (CT)
abdomen/pelvis History of hypocalcemia or seizure disorder Patients with known
hypersensitivity to any of the components of cinacalcet (cinacalcet hydrochloride)